- Home
- FSM vs DNLI Comparison
FSM vs DNLI Comparison
Compare FSM & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSM
- DNLI
- Stock Information
- Founded
- FSM 1990
- DNLI 2013
- Country
- FSM Canada
- DNLI United States
- Employees
- FSM N/A
- DNLI N/A
- Industry
- FSM Precious Metals
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FSM Basic Materials
- DNLI Health Care
- Exchange
- FSM Nasdaq
- DNLI Nasdaq
- Market Cap
- FSM 2.8B
- DNLI 2.2B
- IPO Year
- FSM N/A
- DNLI 2017
- Fundamental
- Price
- FSM $7.84
- DNLI $14.93
- Analyst Decision
- FSM Hold
- DNLI Strong Buy
- Analyst Count
- FSM 1
- DNLI 13
- Target Price
- FSM $10.50
- DNLI $32.64
- AVG Volume (30 Days)
- FSM 15.2M
- DNLI 1.5M
- Earning Date
- FSM 11-05-2025
- DNLI 11-03-2025
- Dividend Yield
- FSM N/A
- DNLI N/A
- EPS Growth
- FSM 7355.92
- DNLI N/A
- EPS
- FSM 0.50
- DNLI N/A
- Revenue
- FSM $1,187,211,000.00
- DNLI N/A
- Revenue This Year
- FSM N/A
- DNLI N/A
- Revenue Next Year
- FSM $9.78
- DNLI $94,232.03
- P/E Ratio
- FSM $15.70
- DNLI N/A
- Revenue Growth
- FSM 46.81
- DNLI N/A
- 52 Week Low
- FSM $4.13
- DNLI $10.57
- 52 Week High
- FSM $9.82
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- FSM 41.02
- DNLI 42.86
- Support Level
- FSM $7.70
- DNLI $15.53
- Resistance Level
- FSM $8.33
- DNLI $17.02
- Average True Range (ATR)
- FSM 0.36
- DNLI 0.79
- MACD
- FSM -0.09
- DNLI -0.19
- Stochastic Oscillator
- FSM 9.00
- DNLI 0.71
About FSM Fortuna Silver Mines Inc (Canada)
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'Ivoire, Mexico, and Peru. The company's segment consists of Mansfield, Sanu, Sango, Cuzcatlan, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d'Ivoire location.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.